Beta Drugs Limited (NSE:BETA)

India · Delayed Price · Currency is INR

2,327.70

+32.70 (1.42%)

At close: Aug 21, 2026

18.85% (1Y)

Market Cap	23.50B +18.8%
Revenue (ttm)	4.10B +10.1%
Net Income	455.86M +8.8%
EPS	44.31 +6.8%
Shares Out	10.09M
PE Ratio	52.53
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,277
Open	2,285.00
Previous Close	2,295.00
Day's Range	2,258.30 - 2,354.10
52-Week Range	990.10 - 2,807.90
Beta	-0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1985

Employees 399

Stock Exchange National Stock Exchange of India

Ticker Symbol BETA

Full Company Profile

Financial Performance

In fiscal year 2026, Beta Drugs's revenue was 3.85 billion, an increase of 6.20% compared to the previous year's 3.62 billion. Earnings were 414.83 million, a decrease of -2.21%.

Financial Statements